2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Melanoma
23
Neoplasms
19
Neoplasm Metastasis
19
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
13
Skin Neoplasms
12
Head and Neck Neoplasms
10
Recurrence
9
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Squamous Cell
8
Carcinoma, Basal Cell
8
Breast Neoplasms
8
Urinary Bladder Neoplasms
7
Carcinoma, Merkel Cell
7
Triple Negative Breast Neoplasms
6
Colonic Neoplasms
6
Carcinoma
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Pancreatic Neoplasms
5
Stomach Neoplasms
4
Sarcoma
4
Multiple Myeloma
4
Mouth Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
cemiplimab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled